In contrast, results from Bugatti’s analysis indicate that, despite inflammation suppression, spine BMD is sensitive to systemic bone loss in ACPA-positive early RA patients during the first 2 years after treatment onset (42). The gene discussed is PRTN3; the disease is rheumatoid arthritis.